Abstract Number: 181 • 2016 ACR/ARHP Annual Meeting
Functional and Quantitative Changes of CCR6+ type3 Innate Lymphoid Cells in Murine Collagen-Induced Arthritis
Background/Purpose: Innate lymphoid cells (ILCs) are a group of lymphocytes that lack antigen-specific receptors and have important roles in mediating immune responses and in regulating…Abstract Number: 182 • 2016 ACR/ARHP Annual Meeting
Histone Methylation in γδ T Cells As a Biomarker of Behcet’s Disease Activity
Background/Purpose: Behcet’s disease (BD) is a chronic recurrent, multisystem inflammatory disorder. The phenotypic characteristics include oral aphtha, genital ulcers, uveitis and skin lesions. No specific…Abstract Number: 183 • 2016 ACR/ARHP Annual Meeting
Protective Role of Mucosal-Associated Invariant T (MAIT) Cells in an Imiquimod-Induced Psoriasis Model
Background/Purpose: Psoriasis is a chronic inflammatory disease of the skin and is often accompanied by arthritis. The underlying pathogenesis of psoriasis is still unclear, but…Abstract Number: 184 • 2016 ACR/ARHP Annual Meeting
Upregulation and Activation of the IFI16-Sting-IRF3-IFN Pathway in Sjogren’s Salivary Glands
Background/Purpose: Type I IFN expression is known to be upregulated in the salivary glands of patients with SjogrenÕs syndrome, but the upstream stimuli responsible for…Abstract Number: 185 • 2016 ACR/ARHP Annual Meeting
The Interferon Gene Signature Is Increased in Early DMARD Naive Rheumatoid Arthritis and Predicts a Poorer Response to Initial Therapy
Background/Purpose: Type 1 interferons, such as interferon-α, are of increasing interest in autoimmunity due to their pleiotropic effects on the immune system. Approximately 20-30% of…Abstract Number: 186 • 2016 ACR/ARHP Annual Meeting
Impact of TLR Stimulation on Cytokine Production in Macrophage Subsets: TLR2 Stimulation Impairs Anti-Inflammatory Activity of M2 Macrophages
Background/Purpose: Toll-like receptors (TLRs) have been shown to contribute to the inflammatory response in rheumatoid arthritis (RA). A number of TLRs have been found to…Abstract Number: 187 • 2016 ACR/ARHP Annual Meeting
Commensal Microbiota Tune Systemic Toll-like Receptor-Mediated Inflammatory Responses
Background/Purpose: Although commensal microbiota are thought to contribute to the development of autoimmunity, the cellular and molecular mechanisms connecting changes in gut microbiota to the…Abstract Number: 188 • 2016 ACR/ARHP Annual Meeting
Responsiveness to X-Linked Toll-like Receptors Differs Between Mice with XY and XX Sex Chromosome Complement, Regardless of the Gonadal Sex
Background/Purpose: Males and females differ in mounting immune response to pathogens. Females appear immune privileged, mounting stronger immune response to pathogens and vaccination. While this…Abstract Number: 189 • 2016 ACR/ARHP Annual Meeting
Nutraceutical Therapy with Polyphenol-Rich Pomegranate Fruit Extract (POMx) Inhibits Systemic NFκB-Mediated Inflammation in a Murine Model of Endotoxemia
Background/Purpose: The pomegranate fruit is cultivated worldwide for dietary consumption, but has been used therapeutically in Eastern medicine from times dating back to ancient Egypt…Abstract Number: 190 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics, Pharmacodynamics, and Tolerability of Verinurad, a Selective Uric Acid Reabsorption Inhibitor, in Healthy Adult Male Subjects
Background/Purpose: This was a Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study. Panels of 8 male subjects (6 active, 2 placebo) received a…Abstract Number: 191 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Febuxostat in Healthy Adult Male Subjects
Background/Purpose: Verinurad (RDEA3170) is a novel selective uric acid reabsorption inhibitor in clinical development for the treatment of gout and asymptomatic hyperuricemia. This Phase 1,…Abstract Number: 192 • 2016 ACR/ARHP Annual Meeting
Pharmacodynamic and Pharmacokinetic Study of Verinurad in Adult Male Subjects with Mild, Moderate, and Severe Renal Impairment: A Phase 1, Open-Label Study
Background/Purpose: Verinurad (RDEA3170) is a high-affinity, selective URAT1 inhibitor in development for the treatment of gout and asymptomatic hyperuricemia. This Phase 1, single-dose, open-label study…Abstract Number: 193 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics, Pharmacodynamics, and Tolerability of Verinurad, a Selective Uric Acid Reabsorption Inhibitor, in Healthy Japanese Male Subjects
Background/Purpose: This was a Phase 1, randomized, single-blind, placebo-controlled study (. Panels of 8 Japanese male subjects were randomized in a 3:1 ratio to receive…Abstract Number: 194 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects with Gout
Background/Purpose: Verinurad (RDEA3170) is a novel selective uric acid reabsorption inhibitor in clinical development for the treatment of hyperuricemia and gout. This Phase 1, single-blind,…Abstract Number: 195 • 2016 ACR/ARHP Annual Meeting
Pharmacodynamics, Pharmacokinetics, and Safety of Verinurad in Combination with Febuxostat Versus Febuxostat Alone and Verinurad Alone in Japanese Adults with Gout or Asymptomatic Hyperuricemia: A Phase 2a, Open-Label Study
Background/Purpose: Verinurad (RDEA3170) is a high-affinity URAT1 inhibitor in development for the treatment of gout and asymptomatic hyperuricemia. This Phase 2a, randomized, open-label, single-site study…
ACR Meeting Abstracts